Resverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment. The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study.
top of page
Recent Posts
See AllThe meeting date assigned by the FDA is June 9, 2024
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research a
Using the platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures ..
bottom of page